Skip to main content
Figure 2 | Alzheimer's Research & Therapy

Figure 2

From: A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease

Figure 2

AZD0530 peripheral target engagement. Four-week treatment with 100 mg and 125 mg AZD0530 reduces serum cross-linked C-telopeptide of type 1 collagen (sCTX), a marker of osteoclast activity. Compared to placebo, mean difference in the change in sCTX from baseline for 50 mg was 51% (95% confidence interval, −22.0 to 124.3), for 100 mg 85% (95% confidence interval, 8.2 to −161.6), and for 125 mg 83% (95% confidence interval, 6.2 to 159.6). **P < 0.05, analysis of variance with Dunnet’s multiple comparisons test. n.s., Not significant.

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193